Titan Pharmaceuticals, the Trilogy

Titan Pharmaceuticals (TTNP) was in the news once again. After news hit the wires this morning that Canadian company Knight Therapeutics launched PROBUPHINE for treatment of opioid disorder, TTNP shares rallied over 13.2% higher premarket. Knight has exclusive rights to distribute PROBUPHINE per an agreement with TTNP. However, TTNP shares retraced the overnight gains throughout the session. Here’s a recap of what happened.